Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:1285-1291

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, A. F.
Right arrow Articles by Carey, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, A. F.
Right arrow Articles by Carey, R. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Other hypertension
Right arrow Hypertension - basic studies

(Hypertension. 2001;37:1285.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Selective Inhibition of the Renal Angiotensin Type 2 Receptor Increases Blood Pressure in Conscious Rats

Allan F. Moore; Nicolas T. Heiderstadt; Esther Huang; Nancy L. Howell; Zhi-Qin Wang; Helmy M. Siragy; Robert M. Carey

From the Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia Health System, Charlottesville.

Abstract—The angiotensin II type 2 (AT2) receptor is present in rat kidney; however, its function is not well understood. The purpose of this study was to evaluate the role of the AT2 receptor in blood pressure (BP) regulation. The effects of selective inhibition of the renal AT2 receptor with phosphorothioated antisense oligodeoxynucleotide (AS-ODN) were examined in conscious uninephrectomized rats. Oligodeoxynucleotides (AS-ODN or scrambled [S-ODN]) were infused directly into the renal interstitial space by using an osmotic pump at 1 µL/h for 7 days. Texas red–labeled AS-ODN was distributed in renal tubules in the infused but not the contralateral kidney of normal rats. Continuous renal interstitial infusion of the AS-ODN, but not S-ODN, caused a significant (P<0.01) increase in BP 1 to 5 days after the initiation of the infusion. AS-ODN–treated rats experienced an increase in systolic BP from 109±4 to 130±4 mm Hg (n=8, P<0.01), whereas S-ODN–treated (n=8) and vehicle-treated (n=8) rats did not show any significant change in BP. On day 5 of the oligodeoxynucleotide infusion, AS-ODN–treated rats exhibited a greater pressor response to systemic angiotensin II infusion (30 ng/kg per hour) than did S-ODN–treated rats (P<0.01). Renal interstitial fluid cGMP decreased from 11.9±0.8 to 3.6±0.5 pmol/mL (P<0.001), and bradykinin decreased from 0.05±0.05 to 0.18±0.03 ng/mL (P<0.001) in response to AS-ODN, but they were not significantly changed in response to S-ODN. To evaluate the effects of AS-ODN and S-ODN on AT2 receptor expression, Western Blot analysis was performed on treated kidneys. Kidneys treated with AS-ODN had {approx}40% less expression of AT2 receptor than did kidneys treated with S-ODN or vehicle (P<0.05). These results suggest that AS-ODN directed selectively against the renal AT2 receptor decreased receptor expression and caused an increase in BP. We conclude that the renal AT2 receptor plays an important role in the regulation of BP via a bradykinin/cGMP vasodilator signaling cascade.


Key Words: blood pressure • receptors, angiotensin II • hypertension, experimental • kidney • rats




This article has been cited by other articles:


Home page
HypertensionHome page
T. A. Barker, M. P. Massett, V. A. Korshunov, A. M. Mohan, A. J. Kennedy, and B. C. Berk
Angiotensin II Type 2 Receptor Expression After Vascular Injury: Differing Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade
Hypertension, November 1, 2006; 48(5): 942 - 949.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. McMullen and S. C. Langley-Evans
Sex-Specific Effects of Prenatal Low-Protein and Carbenoxolone Exposure on Renal Angiotensin Receptor Expression in Rats
Hypertension, December 1, 2005; 46(6): 1374 - 1380.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Guimaraes and H. Pinheiro
Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally
Cardiovasc Res, August 1, 2005; 67(2): 208 - 215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. McMullen and S. C. Langley-Evans
Maternal low-protein diet in rat pregnancy programs blood pressure through sex-specific mechanisms
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R85 - R90.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
H. Gong, Y.-X. Wang, Y.-Z. Zhu, W.-W. Wang, M.-J. Wang, T. Yao, and Y.-C. Zhu
Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat
J Appl Physiol, December 1, 2004; 97(6): 2228 - 2235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Olson, R. Oeckler, X. Li, L. Du, F. Traganos, X. Zhao, and T. Burke-Wolin
Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor
Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L559 - L568.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
V. M. Vehaskari, T. Stewart, D. Lafont, C. Soyez, D. Seth, and J. Manning
Kidney angiotensin and angiotensin receptor expression in prenatally programmed hypertension
Am J Physiol Renal Physiol, August 1, 2004; 287(2): F262 - F267.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
H. Wang, S. Gallinat, H.-w. Li, C. Sumners, M. K. Raizada, and M. J. Katovich
Elevated blood pressure in normotensive rats produced by 'knockdown' of the angiotensin type 2 receptor
Exp Physiol, May 1, 2004; 89(3): 313 - 322.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X.-H. Jin, H. E. McGrath, J. J. Gildea, H. M. Siragy, R. A. Felder, and R. M. Carey
Renal Interstitial Guanosine Cyclic 3', 5'-Monophosphate Mediates Pressure-Natriuresis Via Protein Kinase G
Hypertension, May 1, 2004; 43(5): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. T. Andresen, G. G. Romero, and E. K. Jackson
AT2 Receptors Attenuate AT1 Receptor-Induced Phospholipase D Activation in Vascular Smooth Muscle Cells
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 425 - 431.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
H. Cai, Z. Li, S. Dikalov, S. M. Holland, J. Hwang, H. Jo, S. C. Dudley Jr., and D. G. Harrison
NAD(P)H Oxidase-derived Hydrogen Peroxide Mediates Endothelial Nitric Oxide Production in Response to Angiotensin II
J. Biol. Chem., December 6, 2002; 277(50): 48311 - 48317.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Cervenka, V. Horacek, I. Vaneckova, J. A. Hubacek, M. I. Oliverio, T. M. Coffman, and L. G. Navar
Essential Role of AT1A Receptor in the Development of 2K1C Hypertension
Hypertension, November 1, 2002; 40(5): 735 - 741.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. P. Bagby, L. S. LeBard, Z. Luo, B. E. Ogden, C. Corless, E. D. McPherson, and R. C. Speth
ANG II AT1 and AT2 receptors in developing kidney of normal microswine
Am J Physiol Renal Physiol, October 1, 2002; 283(4): F755 - F764.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365.
[Abstract] [Full Text] [PDF]